2025 Abstracts and Poster Presentations
NASP is pleased to present the publication peer-reviewed abstracts that are part of the NASP 2025 Annual Meeting & Expo. NASP extends its heartfelt appreciation to the authors who are participating in the poster display of their work and are on hand to answer attendee questions to further expound on their research and results.
Publication
View all 2025 published abstracts in the Taylor & Francis MEDLINE-indexed journal Current Medical Research & Opinion (CMRO).
Abstracts accepted for presentation at the NASP Annual Meeting & Expo must reflect completed research and are based on the following: novelty of the research, significance of the findings, relevance to specialty pharmacy, and clarity. Submission of previously presented research is permitted.
2025 Poster Winners
With NASP members serving as poster judges, award winners were announced on Tuesday, September 16, 2025, in the following categories:
- Specialty Pharmacy Outcomes & Practice-Based Research: “Patient Reported Outcomes, and Adherence among Patients with Multiple Sclerosis Treated with Disease Modifying Therapies at an Integrated Health System Specialty Pharmacy.” Lead author: Bisni Narayanan, Yale New Haven Health System.
- Specialty Pharmacy Products, Services, or Programs: “Utilization of a health-system specialty pharmacy to optimize management of HCV-positive kidney transplant recipients.” Lead author: Andrew Wash*, CPS Solutions, LLC
- Digital Engagement/Technology in Specialty Pharmacy Services: “Optimizing specialty medication access through multi-step order transmittal (MSOT) workflows: a single health system evaluation.” Lead author: Diana Le*, UVA Health System
- Attendee Choice: “Identification of a feasible, evidence-based approach to ulcerative colitis disease assessment by specialty pharmacies.” Lead author: Megan Rees, Loopback Analytics
To view abstract posters, please click on the abstract titles below.
OPR01-OR: Impact of expanding Belzutifan to an integrated health-system specialty pharmacy
Brooke Looney*, Vanderbilt Specialty Pharmacy; Jordan Whitehead, Vanderbilt University Medical Center; Catherine Faulkner, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt University Medical Center; Josh DeClercq, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Chelsea Renfro, Vanderbilt University Medical Center
OPR02-EN: Clinical characteristics and treatment persistence in US patients with HR+/HER2-, node positive early breast cancer treated with Abemaciclib: real-world study from first year after approval
Wambui Gathirua-Mwangi, Eli Lilly and Company; Kathryn Hudson, Texas Oncology; Zhanglin Cui, Eli Lilly and Company; Madeline Richey, Flatiron Health; Brenda Grimes, Eli Lilly and Company; Jingru Wang, Flatiron Health; Astra Liepa, Eli Lilly and Company; Erich Brechtelsbauer, Eli Lilly and Company; Raisa Volodarsky, Eli Lilly and Company; Katheryn Moreira, Eli Lilly and Company; Hatem Soliman, Moffitt Cancer Center and Research Institute; Jay Barcelon**, Eli Lilly and Company
OPR03-EN: Employee care partners of spouses with Parkinson’s disease: analysis of patient and care partner (direct medical, Rx, and total) costs and care partner lost work time
Richard Brook*, Better Health Worldwide, Inc; Alek Drnach, WorkPartners, LLC; Stephen Schramm, WorkPartners, LLC; Ian Beren, WorkPartners, LLC; Eric Rosenberg, WorkPartners, LLC
OPR04-OR: Costs and lost time for employees whose spouses have dementia and/or Alzheimer’s disease and patient direct costs
Richard Brook*, Better Health Worldwide, Inc; Stephen Schramm, WorkPartners, LLC; Alek Drnach, WorkPartners, LLC; Ian Beren, WorkPartners, LLC; Eric Rosenberg, WorkPartners, LLC
OPR05-EN: Comparing real-world therapeutic dose attainment and dosing trends of valbenazine and deutetrabenazine among patients with tardive dyskinesia (TD) in a US claims database
M. Mercedes Perez-Rodriguez, Icahn School of Medicine at Mount Sinai; Justin Nedzesky, Neurocrine Biosciences, Inc.; Dawn Vanderhoef, Neurocrine Biosciences, Inc.; Michael Serbin, Neurocrine Biosciences, Inc.; Shivani Pandya, IQVIA; Riddhi Doshi, IQVIA; Xiaoyu Zhou, IQVIA; Hyunwoo Kim, Neurocrine Biosciences, Inc.; Morgan Bron, Neurocrine Biosciences, Inc.; Sharon Cahoon-Metzger**, Neurocrine Biosciences, Inc.
OPR06-EN: Once-daily valbenazine for tardive dyskinesia or Huntington’s disease chorea in patients with dysphagia or pill aversion
Sharon Cahoon-Metzger**, Neurocrine Biosciences, Inc.; Mello Hebert, Neurocrine Biosciences, Inc.; Roland Jimenez, Neurocrine Biosciences, Inc.; Linda Rees, Neurocrine Biosciences, Inc.; Alexander Mar, Neurocrine Biosciences, Inc.; Ali Bristow, Neurocrine Biosciences, Inc.; Kira Aldrich, Neurocrine Biosciences, Inc; Jamie Hamill, Neurocrine Biosciences, Inc.; Richard Moore, Neurocrine Biosciences, Inc.; Khodayar Farahmand, Neurocrine Biosciences, Inc.
OPR07-OR: Comprehensive pharmacy services for oncology patients from an integrated health-system specialty pharmacy
Stephanie Liang, Northwell Health Vivo Health; Agnes Cha*, Northwell Health Vivo Health; Nina Chhabra, Northwell Health/Vivo Health Pharmacy; Carissa Escober Doran, Northwell Health Vivo Health; Sherry Rizkalla, Northwell Health Vivo Health
OPR08-OR: The role of specialty pharmacy in coordinating and monitoring gene therapy for Duchenne Muscular Dystrophy: the Elevidys® experience at a single integrated delivery network medical center
Emily Chen*, UVA Specialty Pharmacy; Alisha Atchison, UVA Health; Nathan Hart, UVA Health System; Angela Holian, UVA Specialty Pharmacy; Joshua Weber, UVA Health System
OPR09-OR: The impact of a pharmacist-led patient management program in inflammatory disease patients at a health-system owned specialty pharmacy (HSSP)
Nina Chhabra*, Northwell Health/Vivo Health Pharmacy; Agnes Cha, Northwell Health Vivo Health; Carissa Escober Doran, Northwell Health Vivo Health; Danielle Gatti-Palumbo, Northwell Health/Vivo Health Pharmacy; Almas Hussain, Northwell Health/Vivo Health Pharmacy; Hussain; Sarah Labib, Northwell Health/Vivo Health Pharmacy; Jacqueline Varnyan, Northwell Health/Vivo Health Pharmacy
OPR10-OR: Evaluating pharmacist-led interventions focused on infection management in inflammatory conditions at a health-system specialty pharmacy
Kelsi Conant*, WVUH Specialty Pharmacy & Home Infusion; Morgan Petitte, WVUMedicine Specialty Pharmacy & Home Infusion
OPR11-OR: Evaluating health system time demands and challenges of specialty pharmacy accreditation
Megan Henry, Shields Health Solutions; Adam Cosby*, Shields Health Solutions; Kate Campagnola, Shields Health Solutions; Patrick Ryan, Shields Health Solutions; Lauren Babits, Shields Health Solutions
OPR12-EN: Comparing rates of turnaround time, adherence, and persistence among patients at Vanderbilt Specialty Pharmacy compared to external specialty pharmacies
Katie Cruchelow*, Vanderbilt Health System; Sarah Layne, Belmont University School of Pharmacy; Josh DeClercq, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt University Medical Center
OPR13-EN: Comparing rates of primary medication nonadherence among patients at Vanderbilt Specialty Pharmacy compared to external specialty pharmacies
Sarah Layne, Belmont University School of Pharmacy; Josh DeClercq, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt University Medical Center; Katie Cruchelow**, Vanderbilt Health System
OPR14-OR: Identifying and addressing nonadherence risk with a technology-supported, pharmacist-led risk stratification process at a health-system specialty pharmacy
Lily Duong, CPS Solutions, LLC; Courtney Smith, PharmD, Penn State Health Milton S. Hershey Medical Center; Josh Bastain, CPS Solutions, LLC; Pranit Kedarisetty, CPS Solutions, LLC; Khang Tran, CPS Solutions, LLC; Abbas Dewji*, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; James Steigerwalt, Penn State Health Milton S. Hershey Medical Center
OPR15-EN: Evaluation of intervention to improve adherence in patients receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulators
https://naspnet.org/wp-content/uploads/2025/08/2127-OPR15-EN-Poster-AM25.pdf
Jacee Billings, VytlOne (formerly Maxor); Alicia Morris, VytlOne (formerly Maxor); Bonnie Dugie*, VytlOne (formerly Maxor)
OPR16-EN: Elacestrant plus abemaciclib (ela+abema) combination in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC)
Hope Rugo, City of Hope Comprehensive Cancer Center; Sara M. Tolaney, Dana-Farber Cancer Institute; Nancy Chen, NYU Langone Health; Erika Hamilton, Sarah Cannon Research Institute; Eva Ciruelos, Hospital Universitario 12 de Octubre; Ji-Yeon Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine; Elia Seguí, Medical Oncology Department, Hospital Clínic-August Pi i Sunyer Biomedical Research Institute (IDIBA); Neelima Vidula, Massachusetts General Hospital, Harvard Medical School; Elena López-Miranda, Hospital Universitario Ramón y Cajal; Joyce O’Shaughnessy, Baylor University Medical Center, Texas Oncology, US Oncology; Giuseppe Curigliano, Istituto Europeo di Oncologia, IRCCS, and University of Milano; Javier Cortés, International Breast Cancer Center (IBCC), Quironsalud Group; Alessandro di Sanzo, Menarini Group; Paula Muñoz Romero, Menarini Group; Bartomeu Piza Vallespir, Menarini Group; Alessandro Paoli, Menarini Group; Monica Binaschi, Menarini Group; Lisa Eifler**, Menarini Stemline
No Audio Abstract
OPR17-OR: One shot at a time: pharmacy team driven implementation of long-acting antiretroviral therapy for HIV management and PrEP
Siham Romahi, Clearway Health; Raven Helsop, Clearway Health; Jean Estime**, Clearway Health
OPR18-OR: Implementing hard stop alerts in hospital software: reducing inappropriate continuation of oral oncolytic prescriptions through enhanced safety mechanisms
Tajae Evans*, Novant Health Specialty Pharmacy; Rachel Vaught, Saint Luke’s Health System
OPR19-OR: Using real-world data to understand treatment variations in migraine patients across healthcare settings
Diane Faraone*, PurpleLab; Karina D’Angelo, Parexel International; Andreas Lysandropoulos, Parexel International
OPR20-RP: Impact of a neurology specialty clinical pharmacist on migraine management outcomes: a prospective observational cohort study
Kama Thomas, Froedtert Health; Heather Dalton, Froedtert Health; Bethany Franz*, Froedtert Health; Megan Fleischman, Froedtert Health
OPR21-EN: Post-launch adverse events reported to FDA Adverse Event Reporting System for long-acting injectable buprenorphine
Brian Dawson, Ideal Option; Michael Frost, The Frost Medical Group; Adam Friedman*, Braeburn Inc; Natalie Budilovsky-Kelley, Braeburn Inc; Joshua Cohen, Braeburn Inc
OPR22-EN: Real-world dosing patterns of biologics in Crohn’s disease and ulcerative colitis: a retrospective observational study
Casey Chapman, GI Alliance, Baton Rouge, LA; Aisha Vadhariya, Eli Lilly and Company; Nicholas Bires, Eli Lilly and Company; Brenna Brady, Merative, Ann Arbor, MI; Thomas Creveling, Eli Lilly and Company; Kristin Evans, Merative, Ann Arbor, MI; Tommaso Panni, Eli Lilly and Company; Faye Chan-Diehl, Eli Lilly and Company; Kim McGinnis, Eli Lilly and Company; Wendi Guo*, Eli Lilly
OPR23-OR: Development and implementation of a migraine work productivity and activity impairment assessment process for employed patients in a health-system specialty pharmacy setting
Casey Fitzpatrick, CPS Solutions, LLC; Maria Talos, CPS Solutions, LLC; Amanda Hickman, CPS Solutions, LLC; Hannah Kurtz, CPS Solutions, LLC; Christopher Sidun, CPS Solutions, LLC; Jedd Schlicht, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC; Ashley Zupancic, CPS Solutions, LLC; Amber Skrtic, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC; Brandon Hardin**, CPS Solutions, LLC
OPR24-OR: Evaluating the impact of a health system specialty pharmacist service on identification and resolution of failed Adalimumab biosimilar transitions
https://naspnet.org/wp-content/uploads/2025/08/1150-OPR24-OR-Poster-AM25.pdf
Kiersi Harmon*, CHRISTUS Health; Alexandra Ritenour, CHRISTUS Health
OPR25-OR: Improving adherence in patients taking cycle-directed oral anti-cancer medications
Olivia Howard*, University of Missouri Health Care; Amanda Stiers, University of Missouri Health Care
OPR26-OR: Effects of HIV mode of transmission on medication adherence in children and youth using a specialty pharmacy
Timothy Howze*, St. Jude Children’s Research Hospital; Christian Phillips, St. Jude Children’s Research Hospital; Tiffany Nason, St. Jude Childrens Research Hospital; Susan Carr, St. Jude Children’s Research Hospital; Nehali Patel, St. Jude Children’s Research Hospital
OPR27-OR: The effectiveness of an integrated health system specialty pharmacy in minimizing the amount of time from prescription requests to verification
Edlyn Hwang*, Signature Healthcare – Clearway Health; Robert Pullano, Signature Healthcare – Clearway Health; Caitlin Howard, Signature Healthcare Pharmacy; Cecilia Nguyen, Signature Healthcare – Clearway Health
OPR28-EN: Increased adoption of IL-1 pathway inhibition and the steroid-sparing paradigm shift: temporal trends in recurrent pericarditis treatment from the RESONANCE patient registry
Paul C. Cremer, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine; Michael Garshick, NYU Langone Health; Sushil A. Luis, Mayo Clinic; Ajit Raisinghani, University of California San Diego; Brittany Weber, Brigham and Women’s Hospital; Vidhya Parameswaran, Kiniksa Pharmaceuticals; Allison Curtis, Kiniksa Pharmaceuticals; Allan L. Klein, Cleveland Clinic; John F. Paolini, Kiniksa Pharmaceuticals; Aamer Khan**, Kiniksa Pharmaceuticals
No Audio Abstract
OPR29-OR: Treatment utilization patterns and time to therapy discontinuation in patients with ALK+ metastatic non-small cell lung cancer
https://naspnet.org/wp-content/uploads/2025/08/1167-OPR29-OR-Poster-AM25.pdf
Martha Stutsky, Shields Health Solutions; Michael Latran, Pfizer; Y. Caleb Chun, Shields Health Solutions; Michael Lloyd, Pfizer; Chloe Kim*, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Christopher Barr, Shields Health Solutions
OPR30-EN: Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
Elyse Swallow, Analysis Group; Jessica Maitland, Analysis Group; Kirthana Sarathy, Analysis Group; Ellen Sears, Analysis Group; Yasir Nagarwala, Menarini Group; Janelle DePalantino, Menarini Group; Eric Kruep*, Menarini Stemline; Corey Pelletier, Menarini Group; Sebastian Kloss, Menarini Group; Tomer Wasserman, Menarini Group
No Audio Abstract
OPR31-RP: Evaluating efficiency through workflow productivity metrics in a health system specialty pharmacy
https://naspnet.org/wp-content/uploads/2025/08/3217-OPR31-RP-Poster-AM25.pdf
Kristen Lawrence*, CHRISTUS Health
OPR32-OR: A review of the pharmacist interventions for medication management in pulmonary arterial hypertension (PAH) patients
https://naspnet.org/wp-content/uploads/2025/08/1191-OPR32-OR-Poster-AM25.pdf
Jiaying Li*, MUSC Specialty Pharmacy; Kristin Sigmon, MUSC Specialty Pharmacy; Jennifer Carter, MUSC Health; Kristine Ritenour, MUSC PVD Program; Silvana Mooney, MUSC PVD Program; Denise Sese, MUSC PVD Program; Rahul Argula, MUSC PVD Program
OPR33-EN: Opportunity sizing of oral oncology medication waste at a health system specialty pharmacy
Chelsey Lindner*, Shields Health Solutions; Zarna Patel, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Tincey Wang, Shields Health Solutions; Kleona Kolludra, Shields Health Solutions; Y. Caleb Chun, Shields Health Solutions
OPR34-EN: Health disparities among patients with moderate to severe asthma in a health system with specialty pharmacy: a retrospective chart review
https://naspnet.org/wp-content/uploads/2025/08/2126-OPR34-EN-Poster-AM25.pdf
Monica Littlejohn*, Vanderbilt Specialty Pharmacy; Briana Hunt, Belmont University; Katie Cruchelow, Vanderbilt Specialty Pharmacy; Autumn Zuckerman, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Nicholas Gargurevich, Vanderbilt University Medical Center
OPR35-EN: Impact of ethnicity and socioeconomic status on baseline asthma severity and response to biologic therapy in the first 12 months post biologic initiation
https://naspnet.org/wp-content/uploads/2025/08/2125-OPR35-EN-Poster-AM25.pdf
Monica Littlejohn*, Vanderbilt Specialty Pharmacy; Katie Cruchelow, Vanderbilt Specialty Pharmacy; Autumn Zuckerman, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Nicholas Gargurevich, Vanderbilt University Medical Center
OPR36-EN: Neurology specialty pharmacist interventions in health-system specialty pharmacy vs. external pharmacy patients
Morteza Kaveh, University of Tennessee Health Science Center College of Pharmacy; Katie Cruchelow, Vanderbilt Specialty Pharmacy; Ryan Moore, Department of Biostatistics, Vanderbilt University Medical Center; Kayla Johnson, Vanderbilt Specialty Pharmacy, Vanderbilt Health System; Sabrina Livezey**, Vanderbilt Specialty Pharmacy
OPR37-EN: The impact of an integrated outpatient specialty neurology pharmacist in a non-MS clinical setting
Kayla Johnson, Vanderbilt Specialty Pharmacy, Vanderbilt Health System; Morteza Kaveh, University of Tennessee Health Science Center College of Pharmacy; Ryan Moore, Department of Biostatistics, Vanderbilt University Medical Center; Katie Cruchelow, Vanderbilt Specialty Pharmacy; Sabrina Livezey**, Vanderbilt Specialty Pharmacy
OPR38-OR: Optimizing care and reducing cost: the impact of health-system specialty pharmacists in idiopathic pulmonary fibrosis management
Ana Lopez-Medina*, CPS Solutions, LLC; Ryan VanSice, CPS Solutions, LLC; Nick Pham, CPS Solutions; Andrew Wash, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
OPR39-OR: Real-world insights on biosimilar conversion following Adalimumab originator product formulary exclusion in treatment-experienced patients
Jessica Lynton, Optum Specialty Pharmacy; Kelsey Waruszewksi, Optum Specialty Pharmacy; Jinesh John, Optum; Stephanie LaPointe, Optum; Clarisse Purvis, Optum; Derek Fisckaerly, Optum Specialty Pharmacy; Kelly Mathews*, Optum
OPR40-OR: Identification of a feasible, evidence-based approach to ulcerative colitis disease assessment by specialty pharmacies
Megan Rees, Loopback Analytics; Samantha Mehta, Pfizer; Michael Gannon, Loopback Analytics; Samuel Konstanty, Loopback Analytics; Jason Lynn, Pfizer; Samantha Mehta**, Pfizer
OPR41-OR: Evaluating pharmacist interventions in a health-system specialty pharmacy: impact of embedded clinic pharmacists on specialty pharmacist intervention patterns
Rachel Mitchell*, WVU Medicine; Morgan Petitte, WVU Medicine Specialty Pharmacy & Home Infusion
OPR42-OR: Transforming rare disease management: real-world impact of an integrated health system specialty pharmacy services
Bisni Narayanan, Yale New Haven Health System; Mitchell DelVecchio, Yale New Haven Health; Kimhouy Tong, Yale New Haven Health; Andrew Cadorette, Yale New Haven Health; Tina Do*, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health
OPR43-OR: Patient reported outcomes, and adherence among patients with multiple sclerosis treated with disease modifying therapies at an integrated health system specialty pharmacy
Bisni Narayanan, Yale New Haven Health System; Michele Riccardi, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Tina Do, Yale New Haven Health; Victoria Lucero**, Yale New Haven Health Specialty Pharmacy
OPR44-OR: Evaluation of Mavacamten clinical outcomes at an integrated health system specialty pharmacy one year post implementation
Bisni Narayanan, Yale New Haven Health System; Michele Riccardi, Yale New Haven Health; Terri Sue Rubino*, Yale New Haven Health; Tina Do, Yale New Haven Health
OPR45-EN: Stability of immune globulin intravenous, human-stwk, 10% liquid following pooling and storage in flexible containers
Stacey Ness*, GC Biopharma USA; Alan Huber, GC Biopharma USA; Suzanne Strasters, GC Biopharma USA; Nari Ji, GC Biopharma; JaeWoon Son, GC Biopharma
OPR46-RP: Quantifying the economic value of specialty pharmacy care through pharmacist interventions: a cost avoidance study
Renee Padia*, Ardon Health; Craig Riccardo, Ardon Health Specialty Pharmacy
OPR47-EN: Safety screening completion in patients initiating immune modulating therapy for rheumatologic dermatologic, and inflammatory bowel disease conditions: multisite prospective analysis
https://naspnet.org/wp-content/uploads/2025/08/2104-OPR47-EN-Poster-AM25.pdf
Julia Pate*, Vanderbilt Specialty Pharmacy; Autumn Zuckerman, Vanderbilt University Medical Center; Karen Thomas, University of Illinois Chicago; Nicholas Gargurevich, Vanderbilt University Medical Center; Kimhouy Tong, Yale New Haven Health
OPR48-OR: Quantifying health-system specialty pharmacists’ interventions for patients utilizing external pharmacies
Laura Petry*, Vanderbilt Specialty Pharmacy; Kristen Whelchel, Vanderbilt Specialty Pharmacy; Amy Mitchell, Vanderbilt Specialty Pharmacy; Ryan Moore, Department of Biostatistics, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt University Medical Center
OPR49-EN: Optimizing Maribavir management: role of a health system specialty pharmacy in access, monitoring, and waste reduction
Strong Oboh, Lipscomb University College of Pharmacy; Autumn Zuckerman, Vanderbilt University Medical Center; Nicholas Gargurevich, Vanderbilt University Medical Center; Dustin Donald, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Chelsea Renfro**, Vanderbilt University Medical Center
OPR50-EN: Pharmacist involvement in specialty medication discontinuation and dose changes
Kristen Perciavalle, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Meredith Edelman, University of Tennessee Health Science Center College of Pharmacy; Autumn Zuckerman, Vanderbilt University Medical Center; Josh DeClercq, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Chelsea Renfro**, Vanderbilt University Medical Center
OPR51-OR: Streamlining hepatitis C treatment: implementation of a specialty pharmacist-driven clinical program
Alexandra Ritenour*, CHRISTUS Health; Kiersi Harmon, CHRISTUS Health
OPR52-OR: Evaluating appeal outcomes for insurance non-preferred dermatology specialty medications
Elna Shibu*, Northwestern Medicine Specialty Pharmacy; Kelly Dvorak, Northwestern Medicine; Alexandra Edinger, Northwestern Memorial Hospital
OPR53-RP: Enhancing Hepatitis C treatment outcomes: the collaborative roles of pharmacists and pharmacy technicians
Brenda Shih*, NeighborHealth and Clearway Health
OPR54-EN: Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with Dupilumab: results from the ADapt trial
Jonathan Silverberg, George Washington University School of Medicine and Health Sciences, Washington; Lindsay Ackerman, U.S. Dermatology Partners, Phoenix; Jerry Bagel, Psoriasis Treatment Center of Central New Jersey, East Windsor; Linda Stein Gold, Henry Ford Hospital, Detroit; Andrew Blauvelt, Blauvelt Consulting, LLC, Portland; David Rosmarin, Indiana University School of Medicine, Indianapolis; Raj Chovatiya, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago; Matthew Zirwas, Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley; Gil Yosipovitch, University of Miami Miller School of Medicine, Miami; Jill Waibel, Miami Dermatology and Laser Institute, Miami; Jenny Murase, University of California, San Francisco and Palo Alto Foundation Medical Group, Mountain view; Ben Lockshin, DermAssociates, Silver Spring; Jamie Weisman, (Former employee) Medical Dermatology Specialists, Atlanta; Amber Atwater, (Former employee) Eli Lilly and Company, Indianapolis; Jennifer Proper, Eli Lilly and Company, Indianapolis; Maria Silk, Eli Lilly and Company, Indianapolis; Evangeline Pierce, Eli Lilly and Company, Indianapolis; Maria Lucia Buziqui Piruzeli; Sonia Montmayeur, Eli Lilly and Company, Indianapolis; Christopher Schuster, Eli Lilly and Company, Indianapolis; Jinglin Zhong, IQVIA, Durham; Maria Jose Rueda, Eli Lilly and Company, Indianapolis; Sreekumar Pillai, Eli Lilly and Company, Indianapolis; Eric Simpson, Oregon Health & Science University, Portland; Dhara Shukla**, Eli Lilly and Company
OPR55-EN: Home infusion specialty drugs: pharmacist patient care tasks and time
Michelle Simpson*, National Home Infusion Association; Danell Haines, DH Consulting; David Vermeulen, FlexCare at Home
No Audio Abstract
OPR56-EN: Health-system specialty pharmacists as key players in the early identification of patients with hereditary amyloid transthyretin amyloidosis
Ana Lopez-Medina, CPS Solutions, LLC; Steven Fosnight, CPS Solutions, LLC; Maria Talos, CPS Solutions, LLC; Amber Skrtic*, CPS Solutions, LLC; Kyle Snoke, CPS Solutions, LLC; Christopher Sidun, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
OPR57-EN: Evaluation of autoinjector safety events in health-system specialty pharmacy patients
Addison South*, UK Healthcare; Courtney Queen, University of Kentucky HealthCare Specialty Pharmacy and Infusion Services; Samantha Bochenek, University of Kentucky HealthCare Specialty Pharmacy and Infusion Services; Christian Rhudy, University of Kentucky HealthCare Specialty Pharmacy and Infusion Services
OPR58-OR: Analysis of a health system specialty pharmacy productivity model
https://naspnet.org/wp-content/uploads/2025/08/1151-OPR58-OR-Poster-AM25.pdf
Sarah Thornton*, University of Arkansas for Medical Sciences; Brett Bailey, University of Arkansas for Medical Sciences; Sarah Yelenich, University of Arkansas for Medical Sciences; Hayley Harrington, University of Arkansas for Medical Sciences
OPR59-OR: Specialty pharmacy-driven stockpiling reduction program outcomes and savings
William Trombatt*, Walgreens Specialty Pharmacy; Rachel Anderson, Walgreens Specialty Pharmacy; John Koshan, Walgreens Specialty Pharmacy; Cara Piaggesi, Walgreens Specialty Pharmacy
OPR61-RP: Validation of a pharmacist monitoring toll for patients with inflammatory bowel disease at a heath-system specialty pharmacy
Kristina Heimerl, UW Health; Jaynika Patel, UW Health; James Langley, UW Health; Connie Vo**, UW Health
OPR62-OR: Evaluating the impact of different call cadences of a nurse-led specialty pharmacy outreach program on Ponatinib adherence and persistency
Allison Watson*, AcariaHealth; Misty Rombach, AcariaHealth; Thomas Pouliot, AcariaHealth; Robert Allender, AcariaHealth; Minette James, AcariaHealth
OPR63-OR: Social determinants of health impact on patient perception within a home infusion and specialty pharmacy setting
Leslie Myers, CSI Pharmacy; Michele Way*, CSI Pharmacy; Elizabeth Neal, CSI Pharmacy; Taylor Cathcart, CSI Pharmacy; Edward O’Bryan, CSI Pharmacy; Timothy P Walton, CSI Pharmacy
OPR66-OR: Hematological oral oncolytics: adherence, healthcare cost and utilization
Francis Staskon, Walgreen Co.; Khadijah Khan*, Walgreen Co.; Amy Pfeifer, Walgreen Co.: Lalymar Havern* Walgreens Specialty Pharmacy
OPR67-OR: Ocrelizumab/Hyaluronidase subcutaneous infusion in the outpatient hospital clinic setting: real-world clinic experience
Angela H. Holian* UVA Specialty Pharmacy; Linda L. Morris, UVA Specialty Pharmacy; Robert K. Shin, UVA Health
OPR68-OR: Improving asthma care through patient-reported outcome measure optimization
Casey Fitzpatrick, CPS Solutions, LLC; Andrew Wash*, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC; Lauren Bryant, CPS Solutions, LLC; Nicholas McDonald, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
OPR69-OR: Real-world adherence and treatment outcomes to EGFR-targeted therapies in NSCLC: an integrated health system specialty pharmacy analysis
Bisni Narayanan, Yale New Haven Health; Michael Zummo, Yale New Haven Health; Christopher Territo, Yale New Haven Health; Terri Sue Rubino*, Yale New Haven Health; Tina Do, Yale New Haven Health
OPR70-OR: Health literacy tool for multiple sclerosis patients on specialty medications
Danielle Munoz, UCSF Health; Kathryn Gallison, UCSF School of Pharmacy; Mackenzie Clark, UCSF Health; Lisa Kroon, UCSF Medical Center; Myra Pascua*, University of California-San Francisco
PSP71-OR: Enhancing specialty medication delivery through pharmacist-led integration of subcutaneous injection therapy in a neurology clinic
Angela H. Holian*,UVA Specialty Pharmacy; Linda L. Morris, UVA Specialty Pharmacy; Emily A. Chen, UVA Specialty Pharmacy; Nathan D. Hart, UVA Health System
PSP72-OR: Utilization of a health-system specialty pharmacy to optimize management of HCV-positive kidney transplant recipients
Andrew Wash*, CPS Solutions, LLC; Sandra Poon, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Ana Lopez Medina, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
PSP73-OR: A model to develop and expand an integrated health system specialty pharmacy patient management program
Sarah Wright, Yale New Haven Health; Michele Riccardi, Yale New Haven Health; Sarah Patterson, Yale New Haven Health; John Fitzgerald, Yale New Haven Health; Tina Do*, Yale New Haven Health
PSP74-RP: Prescription for sustainability – environmental, financial, and performance impacts of integrating eco-friendly cold chain packaging
Kristine Chin, UC Davis Health; Kalpan Patel, UCLA Health; Myra Pascua*, University of California- San Francisco; David Mitchell, UCDH; Jeremiah Duby, UC Davis Health
PSP75-EN: Preliminary real-world evidence on the pharmacy benefit uptake of biosimilar products for self-insured employers
Elizabeth Brewster*, Employers Health; Catherine Berger, Employers Health; Courtney Keefe, Employers Health; Tu Doan, Employers Health; Matthew Harman, Employers Health
PSP76-RP: Beyond the prescription: the specialty clinical pharmacist’s role in managing advanced lipid therapy
Amanda Popko, Geisinger; Michael DiMaggio, Geisinger; Susanne Burns*, Geisinger; Allyson Hess, Geisinger
PSP77-OR: Collaborative initiative between health system specialty pharmacy and advanced heart failure program to identify patients with transthyretin amyloidosis
Anthony Donovan*, Nebraska Medicine; Nicolette Kavan, Nebraska Medicine; Marshall Hyden, Division of Cardiology, University of Nebraska Medical Center
PSP78-OR: Technology-driven social determinants of health screening for patients with neurological conditions
Lily Duong*, CPS Solutions, LLC; Shanece Green, CPS Solutions, LLC; Erin Pavlik, Penn State Health Milton S. Hershey Medical Center; Abbas Dewji, CPS Solutions, LLC; Shelby Adwards, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; James Steigerwalt, Penn State Health Milton S. Hershey Medical Center
PSP79-OR: A review of biosimilar adoption in the setting of originator product removal from a health-system specialty pharmacy
Kelly Dvorak*, Northwestern Medicine; Rachel Joseph, Northwestern Medicine
PSP80-OR: The impact of re-training specialty pharmacy outreach technicians on optimizing compliance and productivity
Melanie Ferreira*, Shields Health Solutions; Dawn DiPasquale, Shields Health Solutions; Lindsey Bolster, Shields Health Solutions
PSP81-OR: Driving patient outcomes with the implementation of a social determinants of health (SDOH) network in an imbedded community pharmacy setting
Dana Gress*, Genoa Healthcare; Rachel McKinney, Optum; Sean Loftus, Genoa Healthcare; Stephanie LaPointe, Optum; Clarisse Purvis, Optum; Kelly Mathews, Optum
PSP82-OR: Impact of a health-system specialty pharmacy cascade of care referral service for people living with hepatitis C
Erika Harrington*, Cleveland Clinic; Chanda Mullen, Cleveland Clinic; Kristel Geyer, Cleveland Clinic
PSP83-EN: Evaluation of a pharmacy delivered oncofertility intervention
Lalymar Havern* Walgreens Specialty Pharmacy; Ann Scalia, Walgreen Co; Ed Witt, Walgreen Co; Julie Phonthibsvads, Walgreen Co; Khadijah Khan, Walgreen Co
PSP84-RP: Streamlining hepatitis C management: a collaborative approach between clinical pharmacists and specialty pharmacies
Susanne Burns, Geisinger; Amanda Popko, Geisinger; Allyson Hess*, Geisinger; Sara Gaines, Geisinger
PSP85-EN: Optimizing the timing of pre-approval information exchange (PIE) engagement for oncology products, products for rare diseases, and cell and gene therapies (CGTs)
Ben Penley, Cencora; Tasmina Hydery*, Cencora; Charles Dragovich, Cencora
PSP86-EN: Clinical outcomes evaluation of a pharmacist-led social determinants of health screening and intervention pilot
Irfana Lakada*, Shields Health Solutions; Andrea Idusuyi, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions
PSP87-OR: Implementing a health-system specialty pharmacist-led pharmacogenomic protocol for DPYD genetic testing to optimize Capecitabine safety
Andrew Wash, CPS Solutions, LLC; Diana Nguyen, CPS Solutions, LLC; Ana Lopez-Medina*, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Abbey Hunter, CPS Solutions, LLC; Katie Jo Cash, CPS Solutions, LLC; Kristin Hutchinson, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
PSP88-OR: Evaluating the impact of clinical pharmacist integration on patient care outcomes in a private rheumatology clinic
Jessica Lynton*, Optum Specialty Pharmacy; Madana Kamineni, Optum Specialty Pharmacy; Janelle Vircks, Optum Specialty Pharmacy; Brittany Panico, Summit Rheumatology; Clarisse Purvis, Optum
PSP89-RP: Standardizing specialty pharmacy practices: addressing risk in loading and maintenance dose management
Shelby Braginetz, UVA Health Specialty & Home Delivery Pharmacy; Marie McCreight*, UVA Health Specialty & Home Delivery Pharmacy; Leslie Duval, UVA Health Specialty & Home Delivery Pharmacy
PSP90-OR: Evaluating the impact of a licensed social worker in specialty pharmacy practice
Ryan McDade*, CenterWell Specialty Pharmacy; Kali Sassack, CenterWell Specialty Pharmacy; Megan Winebrenner, CenterWell Specialty Pharmacy; Laura Arce, CenterWell Specialty Pharmacy; Spenser Cox, University of Cincinnati James L. Winkle College of Pharmacy
PSP91-RP: The role of artificial intelligence in streamlining prior authorizations within a health-system specialty pharmacy
Dylan McWilliams*, The Ohio State University Wexner Medical Center; Anneliesa Henslee, The Ohio State University Wexner Medical Center; Trisha Jordan, The Ohio State University Wexner Medical Center; Liz Hall, The Ohio State University Wexner Medical Center; Steve Deerwester, The Ohio State University Wexner Medical Center; Brianne Porter, The Ohio State University College of Pharmacy
PSP92-EN: Clinical and quality outcomes of a bleeding disorder program in a health system specialty pharmacy
Melissa Racine, Shields Health Solutions; Kerry Mello-Parker*, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions
PSP93-OR: Evaluating the specialty APPE experience: satisfaction from student and preceptor perspectives
Nicole Miracle*, UK Healthcare Specialty Pharmacy and Infusion Services; Addison South, UK Healthcare Specialty Pharmacy and Infusion Services; Amelia Le, UK Healthcare Specialty Pharmacy and Infusion Services; Adrienne Matson, UK College of Pharmacy; Tera McIntosh, UK College of Pharmacy; Janet Mills, UK College of Pharmacy; Holly Divine, UK College of Pharmacy
PSP94-RP: Development and implementation of a novel, pharmacist-led, long-acting HIV pre-exposure prophylaxis administration service in a health system outpatient pharmacy
Jennifer Cocohoba, University of California San Francisco (UCSF); Allison Ngan*, University of California San Francisco (UCSF); Angela Mercado, UCSF Medical Center; Lisa Kroon, UCSF Medical Center
PSP95-EN: Clinical, safety, and quality outcomes of a hypertrophic cardiomyopathy clinical pharmacy management program
Anthony Orlando*, Shields Health Solutions; Caitlyn Pepe, Shields Health Solutions; Kerry Mello-Parker, Shields Health Solutions; Robin Anderton, Shields Health Solutions; Sidrah Anjum, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Kenny Yu, NYU Langone Health
PSP96-RP: Clearer skin, smoother care: dermatology pharmacist-provider co-management in isotretinoin therapy for better outcomes and increased provider access
Amanda Popko*, Geisinger; Susanne Burns, Geisinger; Cara Ciamacco, Geisinger
PSP97-EN: The economic benefit of biosimilars in North America: a targeted literature review
Steven Ren*, Fresenius Kabi; Kunal Shastri, Fresenius Kabi; Kerise Clarke, EVERSANA; Margaret Ainslie-Garcia, EVERSANA
PSP98-EN: The economic impact of ustekinumab in the treatment of psoriasis: a targeted literature review
Steven Ren, Fresenius Kabi; Kunal Shastri, Fresenius Kabi; Kerise Clarke, EVERSANA; Margaret Ainslie-Garcia, EVERSANA; Rushmi Mathur**, Fresenius Kabi
PSP99-OR: Revenue and patient volume associated with accreditation-restricted limited distribution drugs in health-system specialty pharmacies
Lauren Babits, Shields Health Solutions; Patrick Ryan* Shields Health Solutions; Kate Campagnola, Shields Health Solutions; Megan Henry, Shields Health Solutions; Adam Cosby, Shields Health Solutions
PSP100-EN: Ambulatory clinical pharmacist impact on coverage determinations for specialty oncology medications
Young Kim, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Kate Smullen*, Shields Health Solutions; Chelsey Lindner, Shields Health Solutions
PSP102-OR: Wilson disease: where hepatology and neurology collide
Samantha Wells*, University of Arkansas for Medical Sciences (UAMS); Natalie Jones, University of Arkansas for Medical Sciences (UAMS) Outpatient Specialty Pharmacy; Sarah Yelenich, University of Arkansas for Medical Sciences (UAMS)
PSP104-RP: Analysis of Appropriate Storage and Stability of Oral Anticancer Agents
Rebecca Freedman, Cleveland Clinic; Kristel Geyer, Cleveland Clinic; Sean Krohn, Cleveland Clinic; Amruth Krishnamurthy, Cleveland Clinic; Jessica Zebrowski, Cleveland Clinic
DTS105-EN: Randomized control trial evaluating effect of electronic early oral anticancer medication monitoring on pharmacist interventions
Brooke Looney*, Vanderbilt Specialty Pharmacy; Tiffany Bui, Northwestern Medicine Specialty Pharmacy; Josh DeClercq, Vanderbilt University Medical Center; Kristen Welchel, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt University Medical Center
DTS106-OR: Evaluating the influence of technology in specialty pharmacy partnerships
James Battaglia*, Claritas Rx
No Audio Abstract
DTS107-RP: AI-powered rapid enrollment in independent copay foundations accelerates funding and prevents therapy drop-off for cidp and mg infusions in a community neurology setting
Mayukh Choudhury*, GetCopayHelp
DTS108-OR: Human-in-the-loop artificial intelligence system for systematic literature review: methodologies, validations, and compliance with guidance in the Nested Knowledge AutoLit software
Kevin M. Kallmes*, Nested Knowledge; Jade Thurnham, Nested Knowledge; Marius Sauca, Nested Knowledge; Ranita Tarchand, Nested Knowledge; Keith R. Kallmes, Nested Knowledge; Jeff Johnson, Nested Knowledge; Karl J. Holub, Nested Knowledge
DTS109-OR: Optimizing specialty medication access through multi-step order transmittal (MSOT) workflows: a single health system evaluation
Diana Le*, UVA Health System; Joshua Weber, UVA Health System; Nathan Hart, UVA Health System
DTS110-EN: Accelerating evidence generation to implementation in cardiometabolic health: establishment of the LATTICE Consortium
Nishil Patel*, Amgen; Laney Jones, Amgen; Ankeet S Bhatt, Kaiser Permanente Northern California; Leandro Boer, Amgen; Gemme Campbell-Salome, Amgen; Erica Davis, Amgen; Nihar Desai, Yale School of Medicine; Jyothis George, Amgen; Ty J Gluckman, Providence Health Institute; Lisa Head, Amgen; Francoise A Marvel, Johns Hopkins University School of Medicine; Marc Penn, Summa Cardiovascular Institute; Eric D Peterson, UT Southwestern Medicine Center; Nishant Shah, Duke University School of Medicine; Katherine Wilemon, Family Heart Foundation; Bethany Kalich, Amgen; Seth S Martin, Johns Hopkins University School of Medicine
No Audio Abstract
DTS111-OR: Piloting the exchange of cancer genomic reports between labs and electronic health records (EHRs) via GenomeX, a part of the HL7 FHIR accelerator
May Terry, The MITRE corporation; Howard Anton, Tempus AI; Kashmira Sawant, Tempus AI; Wanmei Ou, Ontada; James Patterson, The MITRE Corporation; Kevin Power, Children’s Mercy Kansas City; Chamala Srikar, University of Southern California; Children’s Hospital LA; James Chen, Tempus AI; Kelee Petzelt**, Synerio
No Audio Abstract